Approval Of Astellas’ Myrbetriq Shows FDA’s Faith In Post-Marketing Studies
This article was originally published in The Pink Sheet Daily
Executive Summary
Myrbetriq is approved for overactive bladder, but FDA requires trials looking at CV outcomes and malignant events, and lowers the starting dose from the sponsor’s proposal.